Natera CEO Steven Chapman Sells 1,698 Shares for $545,000
The sale was executed under a pre-arranged Rule 10b5-1 plan amended in March 2026, leaving Chapman with 98,199 directly held shares.
Overview
Steven Leonard Chapman, CEO and President of Natera (NASDAQ:NTRA), sold 1,698 shares of common stock on Sept. 1, 2026, according to a recent SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($320.99); post-transaction value based on Sept. 1, 2026, market close ($320.76).
Details
Natera is a leading molecular diagnostics company with a market capitalization of $52.1 billion and TTM revenue of $2.7 billion, positioning it as a significant player in the reproductive and genetic testing market. The company's competitive advantage derives from its proprietary testing platforms, extensive clinical validation, and established relationships with healthcare providers across multiple geographies. Despite current net losses of $192.3 million TTM, Natera demonstrates strong revenue growth and market momentum, reflecting investor confidence in its diagnostic solutions and market expansion potential.
Source
Originally published at www.fool.com.